Skip to content
SUP-T1
Tissue
Pleural effusion
Disease
Lymphoblastic Lymphoma; T-cell
Synonyms
Sup-T1, SUPT-1, SupT-1, Sup T-1, SUP T-1, SUP T1, Sup T1, SupT1, SUPT1, Tsup-1, VB, Stanford University Pediatric T-cell line 1

Documents

SUP-T1

Cell line · Product number 305642

SUP-T1 is a human T-cell lymphoblastic lymphoma (T-LBL) cell line derived from the pleural effusion of a child diagnosed with T-cell non-Hodgkin lymphoma....

€375.00excl. tax and shipping

Customization / Recommendations

In stock
Lot
Recommended (freshest lot)
  • CoA
1

01General information

Description

SUP-T1 is a human T-cell lymphoblastic lymphoma (T-LBL) cell line derived from the pleural effusion of a child diagnosed with T-cell non-Hodgkin lymphoma. It carries the characteristic t(8;14)(q24;q11) chromosomal translocation, which juxtaposes the MYC oncogene to the T-cell receptor alpha/delta (TCRα/δ) locus. This translocation leads to MYC overexpression, promoting cellular proliferation and inhibiting apoptosis, which are key drivers of lymphomagenesis. Due to this genetic hallmark, SUP-T1 serves as an important model for studying the molecular mechanisms underlying aggressive T-cell malignancies and testing targeted therapies.

Genomic analyses of SUP-T1 have identified additional oncogenic alterations, including deletions and rearrangements affecting the CDKN2A gene, a critical tumor suppressor involved in cell cycle regulation. Loss of CDKN2A leads to dysregulated cell cycle progression, further contributing to the aggressive phenotype of this lymphoma. These findings make SUP-T1 a valuable model for investigating both MYC-driven oncogenesis and the role of tumor suppressor loss in T-cell malignancies.

Recent studies utilizing next-generation sequencing (NGS) and transcriptomic profiling have provided deeper insights into the viral status and mutational landscape of SUP-T1. Screening for viral sequences using RNA-Seq data has confirmed that SUP-T1 is free of Epstein-Barr virus (EBV) and other common viral contaminants, ensuring its reliability for controlled in vitro experiments. Additionally, its genetic profile has been incorporated into large-scale pharmacogenomic datasets, which facilitate the identification of targeted therapeutic strategies for T-cell lymphomas. SUP-T1 continues to be a crucial tool in preclinical research, particularly in the development of novel treatments for aggressive T-cell malignancies.

Tissue
Pleural effusion
Disease
Lymphoblastic Lymphoma; T-cell
Synonyms
  • Sup-T1
  • SUPT-1
  • SupT-1
  • Sup T-1
  • SUP T-1
  • SUP T1
  • Sup T1
  • SupT1
  • SUPT1
  • Tsup-1
  • VB
  • Stanford University Pediatric T-cell line 1

02Classification

Organism
Human
Sex
Male
Growth properties
Suspension
Biosafety level
1

03Characteristics

Morphology
Lymphoblast
Cell type
T lymphoblast
Karyotype
92, XXYY, -2, -2, -9, -9, the following markers are present: 2inv(2*) (p21q11), +2inv(2*), del(2*)(Q21), 2del(4)(q31q35), 2del(5)(p13p14), 2del(6)(q23q27), 2inv(14)(q11q32), t(7;9)(q34;q34), der(9)t(7;9)
Doubling time
28 hours

04Identifiers

Citation
SUP-T1 (Cytion catalog number 305642)
NCBI TaxID
9606
Cellosaurus
CVCL_1714

05Expression and susceptibility

Protein expression
Immunoglobulin (cytoplasmic)
Antigen expression
Leu-6 (CD1a) +; Leu-4 (CD3) +; Leu-3 (CD4) +; Leu-1 (CD5) +; Leu-9 (CD7) +; Leu-2a (CD8) +; OKT-10 (CD38) +
Mutational profile
Mutation: EGFR, Simple, p.Cys251Tyr (c.752G>A), Heterozygous; Mutation: KIT, Simple, p.Arg177His (c.530G>A), Heterozygous; Mutation: MET, Simple, p.Arg191Trp (c.571C>T), Heterozygous; Mutation: PIK3CA, Simple, p.Glu545Asp (c.1635G>T), Heterozygous; Mutation: PIK3CA, Simple, p.Glu970Lys (c.2908G>A), Heterozygous; Mutation: PTCH1, Simple, p.Arg682Cys (c.2044C>T), Heterozygous; Mutation: SPRY4, Simple, p.Arg25Trp (c.73C>T), Heterozygous; Mutation: TP53, Simple, p.Arg267Leu (c.800G>T), Heterozygous

06Handling and culture

Culture medium
RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
Incubation atmosphere

37°C, 5% CO2, humidified atmosphere.

Supplements
Supplement the medium with 10% FBS
Seeding density
2-5 x105 cells/mL
Fluid renewal
2 to 3 times per week
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

  7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

  8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

07Quality control and cryopreservation

Sterility

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.

To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

Freeze medium
As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.
Storage conditions

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Shipping conditions

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

08Donor

Donor age
8 years
Ethnicity
Caucasian